MSB 2022 - The road to commercialisation, page-322

I have a question for Ecoool and the Turtles:

If the previous ARDS by Covid trial had of achieved FDA approval, or, for that matter, the upcoming ARDS by Covid trial achieves FDA approval, what stops the medical world from using the cells for other ARDS cases, given that once approval is given then extensions are commonplace?

I can't see Medicos that are treating ARDS worry bout how the ARDS occurred, once the disease has arrived?

The answer impacts the Novartis deal, IMO.

This is my second question to them (follow on):

If extensions for other ARDS treatments would be expected, why would Novartis and Mesoblast enter into a contract for 'All cause ARDS' whilst the ARDS by Covid trial is in progress?



I don't get the 'All Cause ARDS' Novartis deal at all, given the total circumstances, from the beginning.

I'm leading into......perhaps Novartis looked at the Covid ARDS trial results and thought, All Cause ARDS would be impossible to police and manage as if ARDS by Covid gets up, the horse has bolted and they are wasting their time trying to chase it!

It also explains why the negotiations took so long. Trying to lock down the sales by how the patients got the disease would be difficult I imagine and ARDS by Covid approval would be global news.

All academic. Maybe there is no definitive answer??